Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.
We have entered the era of clinical trials to prevent type 1 diabetes mellitus (T1DM). Before 1922, when insulin was first given to a patient with diabetes, a diagnosis of T1DM was considered a death sentence. Advances in treatment for subjects with diabetes are not yet sufficient to prevent the deleterious impact of diabetes on both day-to-day activities and the early morbidity and mortality still associated with the disease. We now understand a great deal about blood glucose regulation and potential health complications associated with long-term T1DM, but the mystery of why, or the pathogenesis of this devastating disease, remains elusive. Great strides toward unraveling this mystery have been made over the past several decades. Even without definitive answers, we are moving from the period of discovery and animal research to the era of clinical trials. In this review, we wish to convey the palpable excitement in the field. It is time to determine if we can safely change the course of T1DM.
Bollyky
Jennifer
J
Diabetes Program, Benaroya Research Institute, Seattle, WA, USA.
Sanda
Srinath
S
Greenbaum
Carla J
CJ
D015551:Autoimmunity; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D011322:Primary Prevention; D012307:Risk Factors; D055502:Secondary Prevention
D007166:Immunosuppressive Agents; D007328:Insulin